Chemoimmunotherapy for relapsed/refractory Mature B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children (SPARKLE Trial): Initial Safety, PK, and Efficacy

Authors

G AA Burke
A Beishuizen
D Bhojwani
B Burkhardt
V Minard-Colin
R Norris
E Kabickova
F G. Pinarli
N Tacyildiz
J de Jong
G Liu
A Howes
K Nottage
M Salman
X W. de Trixe
Mitchell Cairo, New York Medical CollegeFollow

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

6-2019

DOI

10.1002/hon.27_2629

Journal Title

Hematalogical Oncology

Department

Pediatrics

Second Department

Health Behavior and Community Health

Recommended Citation

Burke, G. A., Beishuizen, A., Bhojwani, D., Burkhardt, B., Minard-Colin, V., Norris, R., Kabickova, E., Pinarli, F. G., Tacyildiz, N., de Jong, J., Liu, G., Howes, A., Nottage, K., Salman, M., de Trixe, X. W., & Cairo, M. (2019). Chemoimmunotherapy for relapsed/refractory Mature B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children (SPARKLE Trial): Initial Safety, PK, and Efficacy. Hematalogical Oncology, 37 (52 Suppl.), 57-59. https://doi.org/10.1002/hon.27_2629